Disease Landscape and Forecast Insights

Market outlookAlzheimer’s disease (AD) is a progressive and irreversible brain disorder that leads to a decline in cognitive abilities, affecting memory and causing patients’ quality of life to…

Clarivate Epidemiology’s coverage of Dup15q syndrome comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…

Clarivate Epidemiology’s coverage of spinal muscular atrophy (SMA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of autism spectrum disorder (ASD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of traumatic brain injury comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of IS comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key dementia patient populations, covering 171 countries and more than…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed prevalence of…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

Clarivate Epidemiology’s coverage of progressive supranuclear palsy (PSP) comprises epidemiological estimates of diagnosed prevalence in the major mature pharmaceutical markets of the United…

Clarivate Epidemiology’s coverage of Rett syndrome comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…